Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France
Abstract
:1. Introduction
2. Materials and Methods
- -
- Demographic characteristics of participants;
- -
- General attitudes and perception to vaccines;
- -
- MPXV—personal opinions;
- -
- Personal views—MPXV and vaccines;
- -
- Personal experience with MPXV.
Statistical Analysis
3. Results
4. Discussion
Limitations Section
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Mahase, E. Seven Monkeypox Cases Are Confirmed in England. BMJ 2022, 377, o1239. [Google Scholar] [CrossRef] [PubMed]
- WHO Director-General’s Statement at the Press Conference Following IHR Emergency Committee Regarding the Multi-Country Outbreak of Monkeypox—23 July 2022. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022 (accessed on 17 September 2022).
- Cas de Variole du Singe: Point de Situation au 15 Septembre 2022. Available online: https://www.santepubliquefrance.fr/les-actualites/2022/cas-de-variole-du-singe-point-de-situation-au-15-septembre-2022 (accessed on 17 September 2022).
- Farfour, E.; Lesprit, P.; Chan Hew Wai, A.; Mazaux, L.; Fourn, E.; Majerholc, C.; Bonan, B.; Vasse, M.; Zucman, D. Acute Hepatitis A Breakthrough in MSM in Paris Area: Implementation of Targeted Hepatitis A Virus Vaccine in a Context of Vaccine Shortage. AIDS Lond. Engl. 2018, 32, 531–532. [Google Scholar] [CrossRef] [PubMed]
- Vallée, A.; Farfour, E.; Zucman, D. Monkeypox Virus: A Novel Sexually Transmitted Disease? A Case Report from France. Travel Med. Infect. Dis. 2022, 49, 102394. [Google Scholar] [CrossRef]
- Multi-Country Monkeypox Outbreak: Situation Update. Available online: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON396 (accessed on 17 August 2022).
- Parker, S.; Nuara, A.; Buller, R.M.L.; Schultz, D.A. Human Monkeypox: An Emerging Zoonotic Disease. Future Microbiol. 2007, 2, 17–34. [Google Scholar] [CrossRef] [PubMed]
- Hammerschlag, Y.; MacLeod, G.; Papadakis, G.; Adan Sanchez, A.; Druce, J.; Taiaroa, G.; Savic, I.; Mumford, J.; Roberts, J.; Caly, L.; et al. Monkeypox Infection Presenting as Genital Rash, Australia, May 2022. Eurosurveillance 2022, 27, 2200411. [Google Scholar] [CrossRef] [PubMed]
- Perez Duque, M.; Ribeiro, S.; Martins, J.V.; Casaca, P.; Leite, P.P.; Tavares, M.; Mansinho, K.; Duque, L.M.; Fernandes, C.; Cordeiro, R.; et al. Ongoing Monkeypox Virus Outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull. 2022, 27, 2200424. [Google Scholar] [CrossRef] [PubMed]
- Thornhill, J.P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L.B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M.S.; et al. Monkeypox Virus Infection in Humans across 16 Countries—April-June 2022. N. Engl. J. Med. 2022, 387, 679–691. [Google Scholar] [CrossRef]
- Tarín-Vicente, E.J.; Alemany, A.; Agud-Dios, M.; Ubals, M.; Suñer, C.; Antón, A.; Arando, M.; Arroyo-Andrés, J.; Calderón-Lozano, L.; Casañ, C.; et al. Clinical Presentation and Virological Assessment of Confirmed Human Monkeypox Virus Cases in Spain: A Prospective Observational Cohort Study. Lancet 2022, 400, 661–669. [Google Scholar] [CrossRef]
- Vivancos, R.; Anderson, C.; Blomquist, P.; Balasegaram, S.; Bell, A.; Bishop, L.; Brown, C.S.; Chow, Y.; Edeghere, O.; Florence, I.; et al. Community Transmission of Monkeypox in the United Kingdom, April to May 2022. Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull. 2022, 27, 2200422. [Google Scholar] [CrossRef]
- Lai, C.-C.; Hsu, C.-K.; Yen, M.-Y.; Lee, P.-I.; Ko, W.-C.; Hsueh, P.-R. Monkeypox: An Emerging Global Threat during the COVID-19 Pandemic. J. Microbiol. Immunol. Infect. Wei Mian Yu Gan Ran Za Zhi 2022. [Google Scholar] [CrossRef]
- Bragazzi, N.L.; Kong, J.D.; Mahroum, N.; Tsigalou, C.; Khamisy-Farah, R.; Converti, M.; Wu, J. Epidemiological Trends and Clinical Features of the Ongoing Monkeypox Epidemic: A Preliminary Pooled Data Analysis and Literature Review. J. Med. Virol. 2022. [Google Scholar] [CrossRef] [PubMed]
- Rizk, J.G.; Lippi, G.; Henry, B.M.; Forthal, D.N.; Rizk, Y. Prevention and Treatment of Monkeypox. Drugs 2022, 82, 957–963. [Google Scholar] [CrossRef] [PubMed]
- Costello, V.; Sowash, M.; Gaur, A.; Cardis, M.; Pasieka, H.; Wortmann, G.; Ramdeen, S. Imported Monkeypox from International Traveler, Maryland, USA, 2021. Emerg. Infect. Dis. 2022, 28, 1002–1005. [Google Scholar] [CrossRef] [PubMed]
- Rao, A.K.; Schulte, J.; Chen, T.-H.; Hughes, C.M.; Davidson, W.; Neff, J.M.; Markarian, M.; Delea, K.C.; Wada, S.; Liddell, A.; et al. Monkeypox in a Traveler Returning from Nigeria—Dallas, Texas, July 2021. MMWR Morb. Mortal. Wkly. Rep. 2022, 71, 509–516. [Google Scholar] [CrossRef]
- Larson, H.J.; Jarrett, C.; Schulz, W.S.; Chaudhuri, M.; Zhou, Y.; Dube, E.; Schuster, M.; MacDonald, N.E.; Wilson, R.; SAGE Working Group on Vaccine Hesitancy. Measuring Vaccine Hesitancy: The Development of a Survey Tool. Vaccine 2015, 33, 4165–4175. [Google Scholar] [CrossRef]
- Lucia, V.C.; Kelekar, A.; Afonso, N.M. COVID-19 Vaccine Hesitancy among Medical Students. J. Public Health 2020, 43, 445–449. [Google Scholar] [CrossRef]
- Vallée, A.; Fourn, E.; Majerholc, C.; Touche, P.; Zucman, D. COVID-19 Vaccine Hesitancy among French People Living with HIV. Vaccines 2021, 9, 302. [Google Scholar] [CrossRef]
- WHO Report of the SAGE Working Group on Vaccine Hesitancy. 2014. Available online: Https://Www.Who.Int/Immunization/Sage/Meetings/2014/October/SAGE_working_group_revised_report_vaccine_hesitancy.Pdf (accessed on 24 July 2022).
- Curran, K.G.; Eberly, K.; Russell, O.O.; Snyder, R.E.; Phillips, E.K.; Tang, E.C.; Peters, P.J.; Sanchez, M.A.; Hsu, L.; Cohen, S.E.; et al. HIV and Sexually Transmitted Infections Among Persons with Monkeypox—Eight U.S. Jurisdictions, May 17–July 22, 2022. MMWR Morb. Mortal. Wkly. Rep. 2022, 71, 1141–1147. [Google Scholar] [CrossRef]
- Heskin, J.; Belfield, A.; Milne, C.; Brown, N.; Walters, Y.; Scott, C.; Bracchi, M.; Moore, L.S.; Mughal, N.; Rampling, T.; et al. Transmission of Monkeypox Virus through Sexual Contact—A Novel Route of Infection. J. Infect. 2022, 85, 334–363. [Google Scholar] [CrossRef]
- Miura, F.; van Ewijk, C.E.; Backer, J.A.; Xiridou, M.; Franz, E.; Op de Coul, E.; Brandwagt, D.; van Cleef, B.; van Rijckevorsel, G.; Swaan, C.; et al. Estimated Incubation Period for Monkeypox Cases Confirmed in the Netherlands, May 2022. Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull. 2022, 27, 2200448. [Google Scholar] [CrossRef]
- Vaccines and Immunization for Monkeypox: Interim Guidance, 14 June 2022. Available online: https://www.who.int/publications-detail-redirect/who-mpx-immunization-2022.1 (accessed on 17 August 2022).
- Ntoumi, F.; Zumla, A. Advancing Accurate Metrics for Future Pandemic Preparedness. Lancet 2022, 399, 1443–1445. [Google Scholar] [CrossRef]
- Zumla, A.; Valdoleiros, S.R.; Haider, N.; Asogun, D.; Ntoumi, F.; Petersen, E.; Kock, R. Monkeypox Outbreaks Outside Endemic Regions: Scientific and Social Priorities. Lancet Infect. Dis. 2022, 22, 929–931. [Google Scholar] [CrossRef]
- Simpson, K.; Heymann, D.; Brown, C.S.; Edmunds, W.J.; Elsgaard, J.; Fine, P.; Hochrein, H.; Hoff, N.A.; Green, A.; Ihekweazu, C.; et al. Human Monkeypox—After 40 Years, an Unintended Consequence of Smallpox Eradication. Vaccine 2020, 38, 5077–5081. [Google Scholar] [CrossRef]
- Zambrano, P.G.; Acosta-España, J.D.; Mosquera Moyano, F.; Altamirano Jara, M.B. Sexually or Intimately Transmitted Infections: A Look at the Current Outbreak of Monkeypox in 2022. Travel Med. Infect. Dis. 2022, 49, 102383. [Google Scholar] [CrossRef] [PubMed]
- Brewer, N.T.; Chapman, G.B.; Rothman, A.J.; Leask, J.; Kempe, A. Increasing Vaccination: Putting Psychological Science Into Action. Psychol. Sci. Public Interest J. Am. Psychol. Soc. 2017, 18, 149–207. [Google Scholar] [CrossRef] [PubMed]
- Temsah, M.-H.; Aljamaan, F.; Alenezi, S.; Alhasan, K.; Saddik, B.; Al-Barag, A.; Alhaboob, A.; Bahabri, N.; Alshahrani, F.; Alrabiaah, A.; et al. Monkeypox Caused Less Worry than COVID-19 among the General Population during the First Month of the WHO Monkeypox Alert: Experience from Saudi Arabia. Travel Med. Infect. Dis. 2022, 49, 102426. [Google Scholar] [CrossRef]
- Al-Tawfiq, J.A.; Barry, M.; Memish, Z.A. International Outbreaks of Monkeypox Virus Infection with No Established Travel: A Public Health Concern with Significant Knowledge Gap. Travel Med. Infect. Dis. 2022, 49, 102364. [Google Scholar] [CrossRef]
- Alsanafi, M.; Al-Mahzoum, K.; Sallam, M. Monkeypox Knowledge and Confidence in Diagnosis and Management with Evaluation of Emerging Virus Infection Conspiracies among Health Professionals in Kuwait. Pathogens 2022, 11, 994. [Google Scholar] [CrossRef]
- Riccò, M.; Ferraro, P.; Camisa, V.; Satta, E.; Zaniboni, A.; Ranzieri, S.; Baldassarre, A.; Zaffina, S.; Marchesi, F. When a Neglected Tropical Disease Goes Global: Knowledge, Attitudes and Practices of Italian Physicians towards Monkeypox, Preliminary Results. Trop. Med. Infect. Dis. 2022, 7, 135. [Google Scholar] [CrossRef]
- Sallam, M.; Al-Mahzoum, K.; Al-Tammemi, A.B.; Alkurtas, M.; Mirzaei, F.; Kareem, N.; Al-Naimat, H.; Jardaneh, L.; Al-Majali, L.; AlHadidi, A.; et al. Assessing Healthcare Workers’ Knowledge and Their Confidence in the Diagnosis and Management of Human Monkeypox: A Cross-Sectional Study in a Middle Eastern Country. Healthcare 2022, 10, 1722. [Google Scholar] [CrossRef]
- Fine, P.E.; Jezek, Z.; Grab, B.; Dixon, H. The Transmission Potential of Monkeypox Virus in Human Populations. Int. J. Epidemiol. 1988, 17, 643–650. [Google Scholar] [CrossRef] [PubMed]
PrEP Patients | HIV Patients | ||||
---|---|---|---|---|---|
n = 53 | %/SD | n = 102 | %/SD | p Value | |
Item 1—Do you want to get vaccinated against MPXV? (yes) | 42 | 79.25% | 61 | 59.80% | 0.013 |
Item 2—Age | <0.001 | ||||
18–29 years | 5 | 9.43% | 4 | 3.92% | |
30–39 years | 24 | 45.28% | 13 | 12.75% | |
40–49 years | 14 | 26.42% | 29 | 28.43% | |
50–59 years | 10 | 18.87% | 35 | 34.31% | |
More than 60 years old | 0 | 0.00% | 21 | 20.59% | |
Item 3—Area of Origin | 0.839 | ||||
Africa | 3 | 5.66% | 8 | 7.92% | |
America | 2 | 3.77% | 3 | 2.97% | |
Asia/Oceania | 4 | 7.55% | 4 | 3.96% | |
Europe | 43 | 81.13% | 85 | 84.16% | |
Item 4–Socio-professional status | 0.346 | ||||
Manager | 31 | 58.49% | 53 | 52.48% | |
Employee | 17 | 32.08% | 24 | 23.76% | |
Student | 1 | 1.89% | 3 | 2.97% | |
Retired | 1 | 1.89% | 9 | 8.91% | |
Unemployed | 2 | 3.77% | 10 | 9.90% | |
Item 5—Are you in a “stable” relationship (i.e., relationship for many years, civil union, marriage?) (yes) | 27 | 50.94% | 47 | 47.00% | 0.319 |
Item 6—Do you use means of protection during your sexual intercourse (condoms)? | 0.006 | ||||
Yes | 8 | 15.09% | 30 | 29.70% | |
Sometimes | 30 | 56.60% | 33 | 32.67% | |
Item 7—Do you practice Chemsex? (yes) | 5 | 9.43% | 16 | 16.33% | 0.230 |
Item 8—Have you had any STI (chlamydia, gonorrhea, syphilis) in the past 3 months (yes) | 18 | 33.96% | 16 | 16.16% | 0.014 |
Item 9—Have you been vaccinated against COVID-19 (yes) | 50 | 96.15% | 99 | 98.02% | 0.505 |
Item 10—Do you feel at risk of being infected by MPXV? (yes) | 40 | 75.47% | 45 | 44.55% | <0.001 |
Item 11 Have you ever refused a vaccine because you consider it useless or dangerous.? (yes) | 8 | 15.09% | 12 | 11.88% | 0.577 |
Item 12—Have you ever agreed to get vaccinated despite doubts about its effectiveness? (yes) | 33 | 62.26% | 63 | 62.38% | 0.989 |
Item 13—As an adult, have you ever refused vaccination for reasons other than illness or allergy? (yes) | 3 | 5.66% | 11 | 10.89% | 0.266 |
Item 14—People are getting more vaccines than needed? (yes) | 8 | 15.09% | 19 | 19.00% | 0.543 |
Item 15—Vaccines are important to me to stay healthy. (yes) | 49 | 92.45% | 95 | 95.00% | 0.531 |
Item 16—The proposed human smallpox vaccine is important in reducing the spread of the outbreak. (yes) | 45 | 84.91% | 90 | 89.11% | 0.737 |
Item 17—The human smallpox vaccine should be compulsory for people at risk. (yes) | 31 | 58.49% | 56 | 55.45% | 0.474 |
Item 18—Am-I likely to be more vulnerable to MPXV as a chronically ill patient? (yes) | - | - | 57 | 60.64% | - |
Item 19—Vaccination against MPXV is important for me as a patient with chronic disease. (yes) | - | - | 67 | 71.28% | - |
Item 20—I am concerned about serious side effects from the human smallpox vaccine. (yes) | 17 | 32.08% | 25 | 24.75% | 0.198 |
Item 21—I need more information on the human smallpox vaccine than is given to the public now. (yes) | 26 | 49.06% | 49 | 48.51% | 0.884 |
Item 22—I trust information I receive about the human smallpox vaccine from my doctor(s). (yes) | 43 | 81.13% | 85 | 85.00% | 0.819 |
Item 23—Participant’s experience with MPXV (I personally know someone who has had a MPXV infection. (yes) | 11 | 20.75% | 12 | 11.88% | 0.320 |
Item 24—Participant’s experience with MPXV (I was a contact case for the MPXV. (yes) | 4 | 7.69% | 2 | 1.98% | 0.189 |
Item 25—Number of different sexual partners in the last month (mean/SD) | 5.3 | 4.7 | 2.9 | 4.4 | 0.006 |
Item 26—Number of different sexual partners in the last three months (mean/SD) | 11.8 | 12.2 | 5.5 | 8.3 | 0.002 |
Item 27—Duration of HIV (years) (mean/SD) | . | . | 16.5 | 9.5 | - |
PrEP Patients | HIV Patients | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Vaccine Hesitant Group | Vaccine Acceptance Group | p Value | Vaccine Hesitant Group | Vaccine Acceptance Group | p Value | |||||
Item 1—Do You Want to Get Vaccinated against MPXV? | n = 11 | 20.7% | n = 42 | 79.3% | n = 41 | 40.2% | n = 61 | 59.8% | 0.013 | |
Item 2—Age | 0.834 | 0.345 | ||||||||
18–29 years | 1 | 9.09% | 4 | 9.52% | 1 | 2.44% | 3 | 4.92% | ||
30–39 years | 5 | 45.45% | 19 | 45.24% | 2 | 4.88% | 11 | 18.03% | ||
40–49 years | 2 | 18.18% | 12 | 28.57% | 13 | 31.71% | 16 | 26.23% | ||
50–59 years | 3 | 27.27% | 7 | 16.67% | 16 | 39.02% | 19 | 31.15% | ||
Over 60 years of age | 0 | 0.00% | 0 | 0.00% | 9 | 21.95% | 12 | 19.67% | ||
Item 3—Area of origin | 0.122 | 0.482 | ||||||||
Africa | 0 | 0.00% | 3 | 7.14% | 3 | 7.32% | 5 | 8.33% | ||
America | 0 | 0.00% | 2 | 4.76% | 0 | 0.00% | 3 | 5.00% | ||
Asia/Oceania | 2 | 18.18% | 2 | 4.76% | 1 | 2.44% | 3 | 5.00% | ||
Europe | 8 | 72.73% | 35 | 83.33% | 37 | 90.24% | 48 | 80.00% | ||
Item 4—Socio-professional status | 0.409 | 0.609 | ||||||||
Manager | 6 | 54.55% | 25 | 59.52% | 23 | 57.50% | 30 | 49.18% | ||
Employee | 3 | 27.27% | 14 | 33.33% | 11 | 27.50% | 13 | 21.31% | ||
Student | 1 | 9.09% | 0 | 0.00% | 1 | 2.50% | 2 | 3.28% | ||
Retired | 0 | 0.00% | 1 | 2.38% | 2 | 5.00% | 7 | 11.48% | ||
Unemployed | 1 | 9.09% | 1 | 2.38% | 2 | 5.00% | 8 | 13.11% | ||
Item 5—Are you in a “stable” relationship (i.e., a relationship for many years, civil union, marriage?) (yes) | 6 | 54.55% | 21 | 50.00% | 0.788 | 15 | 38.46% | 32 | 52.46% | 0.346 |
Item 6—Do you use means of protection during your sexual intercourse (condoms)? | 0.701 | 0.662 | ||||||||
Yes | 2 | 18.18% | 6 | 14.29% | 13 | 32.50% | 17 | 27.87% | ||
Sometimes | 7 | 63.64% | 23 | 54.76% | 11 | 27.50% | 22 | 36.07% | ||
Item 7—Do you practice Chemsex? (yes) | 0 | 0.00% | 5 | 11.90% | 0.229 | 6 | 15.00% | 10 | 17.24% | 0.768 |
Item 8—Have you had any STIs (chlamydia, gonorrhea, syphilis) in the past 3 months (yes) | 3 | 27.27% | 15 | 35.71% | 0.598 | 5 | 12.50% | 11 | 18.64% | 0.415 |
Item 9—Have you been vaccinated against COVID-19 (yes) | 9 | 81.82% | 41 | 100.00% | 0.006 | 38 | 95.00% | 61 | 100.00% | 0.078 |
Item 10—Do you feel at risk of being infected by MPXV? (yes) | 5 | 45.45% | 35 | 83.33% | 0.032 | 3 | 7.50% | 42 | 68.85% | <0.001 |
Item 11 Have you ever refused a vaccine because you considered it useless or dangerous? (yes) | 3 | 27.27% | 5 | 11.90% | 0.205 | 10 | 25.00% | 2 | 3.28% | 0.001 |
Item 12—Have you ever agreed to get vaccinated despite doubts about its effectiveness? (yes) | 6 | 54.55% | 27 | 64.29% | 0.553 | 22 | 55.00% | 41 | 67.21% | 0.215 |
Item 13—As an adult, have you ever refused vaccination for reasons other than illness or allergy? (yes) | 3 | 27.27% | 0 | 0.00% | <0.001 | 9 | 22.50% | 2 | 3.28% | 0.002 |
Item 14—People are getting more vaccines than needed. (yes) | 5 | 45.45% | 3 | 7.14% | 0.002 | 13 | 33.33% | 6 | 9.84% | 0.003 |
Item 15—Vaccines are important to me to stay healthy. (yes) | 9 | 81.82% | 40 | 95.24% | 0.133 | 35 | 87.50% | 60 | 100.00% | 0.005 |
Item 16—The proposed human smallpox vaccine is important in reducing the spread of the outbreak. (yes) | 5 | 45.45% | 40 | 95.24% | <0.001 | 31 | 77.50% | 59 | 96.72% | 0.009 |
Item 17—The human smallpox vaccine should be compulsory for people at risk. (yes) | 4 | 36.36% | 27 | 64.29% | 0.239 | 12 | 30.00% | 44 | 72.13% | <0.001 |
Item 18—I’m likely to be more vulnerable to MPXV as a chronically ill patient. (yes) | - | - | - | - | - | 21 | 56.76% | 36 | 63.16% | 0.482 |
Item 19—Vaccination against MPXV is important for me as a patient with chronic disease. (yes) | - | - | - | - | - | 15 | 40.54% | 52 | 91.23% | <0.001 |
Item 20—I’m concerned about serious side effects from the human smallpox vaccine. (yes) | 6 | 54.55% | 11 | 26.19% | 0.049 | 12 | 30.00% | 13 | 21.31% | 0.548 |
Item 21—I need more information on the human smallpox vaccine than is given to the public now. (yes) | 9 | 81.82% | 17 | 40.48% | 0.047 | 21 | 52.50% | 28 | 45.90% | 0.195 |
Item 22—I trust information I receive about the human smallpox vaccine from my doctor(s). (yes) | 8 | 72.73% | 35 | 83.33% | 0.536 | 32 | 80.00% | 53 | 88.33% | 0.215 |
Item 23—Participant’s experience with MPXV (I personally know someone who has had a MPXV infection. (yes) | 1 | 9.09% | 10 | 23.81% | 0.392 | 2 | 5.00% | 10 | 16.39% | 0.199 |
Item 24—Participant’s experience with MPXV (I was a contact case for the MPXV. (yes) | 1 | 9.09% | 3 | 7.32% | 0.803 | 0 | 0.00% | 2 | 3.28% | 0.005 |
Item 25—Number of different sexual partners in the last month (mean/SD) | 2.8 | 2.3 | 6.0 | 4.9 | 0.019 | 1.1 | 1.6 | 3.9 | 5.2 | 0.002 |
Item 26—Number of different sexual partners in the last three months (mean/SD) | 7.8 | 7.7 | 12.9 | 13.1 | 0.149 | 1.8 | 2.6 | 7.9 | 9.7 | 0.001 |
Item 27—Duration of HIV (years) (mean/SD) | . | . | . | . | 17.8 | 9.6 | 15.7 | 9.4 | 0.315 |
PrEP Patients | |||
---|---|---|---|
Parameters | OR | IC 95% | p Value |
Item 14—Are people getting more vaccines than needed? (yes) | 0.10 | [0.02–0.60] | 0.012 |
Item 25—Number of different sexual partners in the last month (per units) | 1.35 | [1.04–1.93] | 0.034 |
HIV patients | |||
Parameters | OR | IC 95% | p value |
Item 10—Do you feel at risk of being infected by MPXV? (yes) | 19.45 | [6.14–33.48] | <0.001 |
Item 17—The human smallpox vaccine should be compulsory for people at risk? (yes) | 15.58 | [4.41–25.07] | <0.001 |
Item 25—Number of different sexual partners in the last month (per unit) | 1.62 | [1.08–2.49] | 0.018 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zucman, D.; Fourn, E.; Touche, P.; Majerholc, C.; Vallée, A. Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France. Vaccines 2022, 10, 1629. https://doi.org/10.3390/vaccines10101629
Zucman D, Fourn E, Touche P, Majerholc C, Vallée A. Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France. Vaccines. 2022; 10(10):1629. https://doi.org/10.3390/vaccines10101629
Chicago/Turabian StyleZucman, David, Erwan Fourn, Pauline Touche, Catherine Majerholc, and Alexandre Vallée. 2022. "Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France" Vaccines 10, no. 10: 1629. https://doi.org/10.3390/vaccines10101629
APA StyleZucman, D., Fourn, E., Touche, P., Majerholc, C., & Vallée, A. (2022). Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France. Vaccines, 10(10), 1629. https://doi.org/10.3390/vaccines10101629